U.S. Markets closed
  • S&P Futures

    4,381.50
    -30.25 (-0.69%)
     
  • Dow Futures

    34,892.00
    -82.00 (-0.23%)
     
  • Nasdaq Futures

    14,855.50
    -182.25 (-1.21%)
     
  • Russell 2000 Futures

    2,226.20
    -11.30 (-0.51%)
     
  • Crude Oil

    73.23
    -0.39 (-0.53%)
     
  • Gold

    1,832.10
    -3.70 (-0.20%)
     
  • Silver

    25.60
    -0.18 (-0.71%)
     
  • EUR/USD

    1.1886
    -0.0010 (-0.0832%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3954
    -0.0004 (-0.0251%)
     
  • USD/JPY

    109.4870
    +0.0260 (+0.0238%)
     
  • BTC-USD

    40,148.81
    +324.15 (+0.81%)
     
  • CMC Crypto 200

    955.20
    +24.84 (+2.67%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,305.27
    -477.15 (-1.72%)
     

Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

·2 min read

Conference call to take place at 8:30 a.m. ET

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

The conference call webcast will be available in the Investors & News section on the company’s website at www.axcellahealth.com. To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company’s website for 90 days following the call.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the "Investors and News" section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005047/en/

Contacts

Company
Jason Fredette
jfredette@axcellahealth.com
857.320.2236